...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Leukemia Research and Treatment >Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature
【24h】

Clinical Experience Using Vitamin D and Analogs in the Treatment of Myelodysplasia and Acute Myeloid Leukemia: A Review of the Literature

机译：使用维生素D和类似物治疗骨髓增生异常和急性髓性白血病的临床经验：文献综述

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Despite progress in understanding the biology of acute myeloid leukemia (AML), and despite advances in treatment, the majority of patients with AML die from the disease. The observation that Vitamin D can induce AML blast cellsin vitroto differentiate along the monocytic lineage was made 30 years ago; however, it remains to translate this into a clinically meaningful strategy. This is a review of published clinical experience regarding the use of Vitamin D and its analogs, either alone or in combination with other agents, to treat AML. In many of these reports, investigators included patients with myelodysplasia (MDS) as well as AML patients in their treatment cohorts; therefore reports of Vitamin D and its analogs in treating MDS are included. This review documents heterogeneity in selection criteria for patients treated in these studies, the spectrum of Vitamin D analogs used in various studies, and the differing dosing strategies employed by investigators. Despite examples of occasional clinical efficacy, barriers remain to the successful application of Vitamin D in the treatment of MDS and AML. These include the lack of definition of a particularly sensitive target population, and the as yet unknown optimal choice of Vitamin D analog and dosing schedule.
机译：尽管在了解急性髓细胞性白血病（AML）的生物学方面取得了进展，并且在治疗方面取得了进步，但大多数AML患者都死于该疾病。 30年前就发现维生素D可以体外诱导AML胚细胞沿单核细胞系分化。然而，仍然需要将其转化为具有临床意义的策略。这是对有关维生素D及其类似物（单独使用或与其他药物联合使用）治疗AML的已发表临床经验的综述。在许多此类报告中，研究者将骨髓增生异常（MDS）患者和AML患者纳入治疗队列。因此，包括维生素D及其类似物治疗MDS的报道。这篇综述记录了这些研究中患者选择标准的异质性，各种研究中使用的维生素D类似物的范围以及研究者采用的不同剂量策略。尽管偶尔有临床功效的实例，但维生素D在MDS和AML的治疗中的成功应用仍然存在障碍。这些包括缺乏对特别敏感的目标人群的定义，以及未知的维生素D类似物和给药方案的最佳选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号